SIBN
SI-BONE, Inc.
SIBN lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink.
SIBN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
SIBN's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
SIBN PE Valuation
SIBN has no meaningful PE right now: it lost money over the past year.
SIBN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect SIBN's losses to shrink, with revenue growing.
SIBN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.31 | +$0.19 |
| Q2 2026 | -$0.34 | +$0.21 |
| Q1 2026 | -$0.39 | +$0.24 |
| Q4 2025 | -$0.44 | +$0.31 |
| Q3 2025 | -$0.50 | +$0.41 |
| Q2 2025 | -$0.55 | +$0.45 |
| Q1 2025 | -$0.63 | +$0.45 |
| Q4 2024 | -$0.75 | +$0.38 |
SIBN is still losing money, but far less than before: $0.31 per share over the past year, against $1.98 at its worst in mid-2022.
SIBN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $55.7M | +14% |
| Q2 2026 | $56M | +15% |
| Q1 2026 | $52.6M | +11% |
| Q4 2025 | $56.3M | +15% |
| Q3 2025 | $48.7M | +21% |
| Q2 2025 | $48.6M | +22% |
| Q1 2025 | $47.3M | +25% |
| Q4 2024 | $49M | +26% |
SIBN's revenue has grown year over year every quarter since late 2020: $56M last quarter, up 14% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.8% | +3.3 points |
| Q2 2026 | -8.6% | +5.8 points |
| Q1 2026 | -9.7% | +6.1 points |
| Q4 2025 | -4.4% | +6.8 points |
| Q3 2025 | -11% | +7.9 points |
| Q2 2025 | -14% | +11 points |
| Q1 2025 | -16% | +16 points |
| Q4 2024 | -11% | +21 points |
SIBN's operating margin was −7.8% last quarter, up 3.3 points from the same quarter a year ago, near the top of its range since 2019.
SIBN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$427K | +$193K |
| Q2 2026 | -$768K | +$1.2M |
| Q1 2026 | -$3.4M | +$3.5M |
| Q4 2025 | $440K | +$1.5M |
| Q3 2025 | -$620K | +$2.1M |
| Q2 2025 | -$1.9M | +$7.5M |
| Q1 2025 | -$7M | +$2.7M |
| Q4 2024 | -$1.1M | +$2.3M |
SIBN has burned cash in almost every quarter: −$4M over the past year, against −$11M the year before.
SIBN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +422K shares |
| 1 year | +4% | +1.7M shares |
| 3 years | +12% | +4.6M shares |
| 5 years | +35% | +11.6M shares |
| Available history | +82% | +20.2M shares |
SIBN has 45M diluted shares, up 4% from a year ago.
SIBN Net Leverage
SIBN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
SIBN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 74.9 | Overbought |
| Stochastic | 76.7 | Neutral |
SIBN's weekly RSI is 75 (overbought) and its Stochastic is 77 (neutral).
SIBN PE vs Healthcare Sector
SIBN has no meaningful PE right now: it lost money over the past year.
SIBN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $20.9 | 16% above |
| 20 week MA | $19.3 | 25% above |
| 50 week MA | $17.1 | 41% above |
| 100 week MA | $16.6 | 45% above |
| 200 week MA | $17.5 | 38% above |
SIBN has climbed back above all five of its weekly moving averages, and it's now 38% above its 200-week average.
SIBN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $21.1 | $30.3 | +43% |
| 2021 | $30.3 | $21.9 | -28% |
| 2022 | $21.9 | $11.8 | -46% |
| 2023 | $11.8 | $21.0 | +78% |
| 2024 | $21.0 | $13.7 | -35% |
| 2025 | $13.7 | $20.4 | +48% |
| 2026 YTD | $20.4 | $24.1 | +19% |
SIBN has finished lower in three of the last six years. It's up 19% so far in 2026.